The company on a sermorelin checkout page rarely made the drug. No FDA-approved sermorelin product exists anymore. Every vial or tablet sold today is compounded, from bulk sermorelin acetate powder, by a licensed pharmacy [1]. The seller runs the website and the intake form. A separate pharmacy, under its own state license, actually prepares what ships. Across the 42 sermorelin provider reviews on this site, checked for this field as of September 14, 2026, exactly one names that pharmacy anywhere on its page.
What “compounded” already tells you, and what it doesn’t
Compounded does not mean unregulated. A compounding pharmacy holds a real license, tied to a real state board. That is true whether or not a seller’s page says so. What compounded does mean is narrower: no single, finished, FDA-approved product exists for anyone to point to. The old approval, under the brand Geref, was discontinued for business reasons decades ago, not a safety finding [1]. See the full approval history for how that discontinuation is distinct from a withdrawal. Every current listing traces back to a pharmacy’s own compounding work instead. Which pharmacy that is, though, is a separate fact. It’s the fact most seller pages leave out.
Two licenses, one meaningful difference
Compounding pharmacies fall into one of two federal categories. Section 503A covers a licensed pharmacist compounding in a state-licensed pharmacy, generally against an individual prescription. 503A compounding is explicitly exempt from federal current good manufacturing practice rules [2]. Section 503B covers outsourcing facilities instead. These are a separate, FDA-registered category that can compound larger batches. Unlike 503A, they are not exempt from that same manufacturing standard [2]. Neither category is automatically the safer choice. They are simply different regulatory arrangements. A buyer cannot tell which one applies without knowing which pharmacy filled the order.
What naming the pharmacy actually adds
A named pharmacy is a checkable fact. A state board of pharmacy license can be looked up by name. So can standing with a compounding-specific accreditation body. So can any public disciplinary record. None of that is possible against a seller’s brand name alone. The seller is not the licensed party doing the compounding. Naming the pharmacy does not certify anything by itself. It simply moves the question from unanswerable to answerable. A buyer who knows the pharmacy’s name can ask a state board something specific. A buyer who only knows the seller’s brand name cannot.
Two kinds of lookup become possible once a pharmacy is named. The first is licensure itself: whether that specific pharmacy holds an active license in the state it ships from, and whether any state board has taken disciplinary action against it. The second is accreditation: whether a pharmacy has sought a third-party compounding accreditation on top of its baseline state license, which is a voluntary step some pharmacies take and others skip. Neither lookup requires special access. Both require a name.
Why this fact sits apart from a certificate of analysis
A certificate of analysis and a named pharmacy answer two different questions, and it’s worth being precise about which is which. A certificate of analysis is about the chemistry of a batch: whether a tested sample was actually sermorelin, at the labeled strength, on a given date. Naming the pharmacy is about the party doing the compounding, full stop, independent of any single batch. A seller can, in principle, publish a certificate of analysis while still never naming who compounded the product it covers. The two disclosures are complementary, not substitutes for one another.
The one count, in full
Among the 42 sermorelin reviews on this site, this field is set, one way or the other, on exactly one review. That review is Breeze Meds, and it is set to false. Breeze Meds’ entire sermorelin listing runs through a single-page storefront with no dedicated product page. Neither its catalog entry nor its homepage card for that product names a compounding pharmacy anywhere [3]. The other 41 reviews leave the field unset. On this site that means something specific: nothing on that seller’s own page established a pharmacy name either way. It does not mean one was checked for and found. As of September 14, 2026, not one of the 42 reviews reports a named compounding pharmacy [4].
What that silence does not mean
An unnamed pharmacy is not evidence of a bad one. Plenty of legitimate direct-to-consumer prescribers route orders through a pharmacy network, not one named partner. Sometimes the fulfilling pharmacy varies by the buyer’s state. Sometimes it’s just an ordinary competitive choice, unrelated to quality. A seller’s silence on this one fact says nothing on its own. It doesn’t say whether the pharmacy is 503A or 503B. It doesn’t say whether that pharmacy is accredited, or in good standing with its state board. It says only that the page in front of the buyer doesn’t answer the question. That gap is real, and it’s common across this category. But it’s a gap in disclosure, not a finding about any particular pharmacy.
What’s worth asking directly
One fact is worth asking a seller for before anything else: the name of the pharmacy that actually compounds the order. A seller that answers plainly, by name, has handed over something a buyer can independently check. A seller that declines, or answers only with its own brand name, has not. That response is itself information, separate from whatever the pharmacy behind it turns out to be. See the telehealth prescribers verified on this site for sellers that run a named, prescriber-led intake rather than a single-page storefront.
A second, related question is worth pairing with the first: whether that pharmacy is the same one for every order, or whether it varies by state or by supply. A seller can answer both questions honestly and still turn out to route through more than one pharmacy depending on where a buyer lives. That is a normal operational fact about a multi-state telehealth business, not a red flag on its own. What matters is whether the seller is willing to say so, rather than leaving the question unanswered entirely. For how sellers frame these claims more broadly, see sermorelin’s marketing claims, ranked by evidence.